CircRNAs play a role in HCC drug resistance; specifically, m6A-modified circSORE enhances HCC sorafenib resistance by activating the Wnt/β-catenin signaling pathway through binding to miR-103a-2-5p and miR-660-3p [96], m6A-modified circMAP3K4 inhibits cisplatin-induced cell death in HCC through its protein circMAP3K4-455aa encoded under the action of IGF2BP1, which inhibits AIF cleavage and nuclear distribution [64]. Here, IGF2BP1 is linked to hepatocellular carcinoma.